CAJ | 학술논문

目的：观察噻托溴铵粉雾剂治疗慢性阻塞性肺病( COPD)的临床疗效及安全性。方法选取122例COPD患者采用信封法随机分为2组,两组患者均给予沙丁胺醇气雾剂吸入、抗生素抗感染等常规对症支持治疗。对照组62例患者在上述治疗基础上,吸入异丙托溴铵,2喷/次,3次/d。同时采用与观察组噻托溴铵粉雾剂外观相同的安慰剂吸入。观察组60例吸入噻托溴铵粉雾剂,18μg/次,每天1次,同时采用与爱全乐气雾剂相同外观的安慰剂吸入。分别在两组患者治疗前、治疗6周后、治疗12周后测定 FEV1(第一秒用力呼气量)、FVC(用力肺活量)、FEV1/FVC(第一秒率)。观察两组患者治疗期间不良反应发生情况。结果观察组临床症状改善率为93．33%,对照组为77．42%,观察组改善率明显高于对照组( P<0．05)。观察组治疗后6周及12周时,FEV1、 FVC及FEV1/FVC均明显高于治疗前及对照组治疗后(P<0．05)。观察组不良反应发生率低于对照组,但差异无统计学意义(P>0．05)。结论噻托溴铵粉雾剂用于 COPD患者的治疗,可明显改善患者临床症状,改善患者肺功能,不良反应发生率低,疗效确切,安全可靠。
목적：관찰새탁추안분무제치료만성조새성폐병( COPD)적림상료효급안전성。방법선취122례COPD환자채용신봉법수궤분위2조,량조환자균급여사정알순기무제흡입、항생소항감염등상규대증지지치료。대조조62례환자재상술치료기출상,흡입이병탁추안,2분/차,3차/d。동시채용여관찰조새탁추안분무제외관상동적안위제흡입。관찰조60례흡입새탁추안분무제,18μg/차,매천1차,동시채용여애전악기무제상동외관적안위제흡입。분별재량조환자치료전、치료6주후、치료12주후측정 FEV1(제일초용력호기량)、FVC(용력폐활량)、FEV1/FVC(제일초솔)。관찰량조환자치료기간불량반응발생정황。결과관찰조림상증상개선솔위93．33%,대조조위77．42%,관찰조개선솔명현고우대조조( P<0．05)。관찰조치료후6주급12주시,FEV1、 FVC급FEV1/FVC균명현고우치료전급대조조치료후(P<0．05)。관찰조불량반응발생솔저우대조조,단차이무통계학의의(P>0．05)。결론새탁추안분무제용우 COPD환자적치료,가명현개선환자림상증상,개선환자폐공능,불량반응발생솔저,료효학절,안전가고。
Objective To observe the clinical efficacy and safety of tiotropium treatment for chronic obstruc-tive pulmonary disease ( COPD) . Methods 122 cases of COPD patients were randomly divided into two groups using the envelope method,patients were given albuterol inhalation aerosol,antibiotic-resistant infections and other conven-tional treatment. 62 patients in the control group on the basis of the above treatment with ipratropium bromide inhala-tion,two spray per time,3 times a day. While using placebo inhalation looked like tiotropium of the observation group. 60 patients in the observation group inhaled tiotropium 18 μg per time a day,while using the placebo inhalation looked like atrovent aerosol. Before treatment and after 6 weeks and 12 weeks treatment,FEV1 ( forced expiratory volume in one second),FVC (forced vital capacity),FEV1/FVC (first second rate) were measured of the two groups and the adverse events were recorded during treatment. Results The clinical improvement rate was 93. 33% in the control group,and it was 77. 42% in the observation group, there was significant difference between the two groups ( P <0. 05). After 6 weeks and 12 weeks treatment,FEV1,FVC and FEV1/FVC of the observation group were significantly higher than those before treatment and control group ( P<0. 05 ) . The adverse reaction rate of observation group was lower than that of the control group,but the difference was not significant (P>0. 05). Conclusion Tiotropium treat-ment for the patients with COPD can significantly improve the clinical symptoms and lung function,decrease the inci-dence of adverse reactions,and has better efficacy,it is safe and reliable.